Ovid Therapeutics Inc. (OVID)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 6.3M | 132K | 718K | 0.00 |
| Operating Income | -5.1M | -12.5M | -12.3M | -17.8M |
| Net Income | -4.7M | -12.2M | 9.7M | -17.0M |
| Diluted EPS | $-0.06 | $-0.17 | $0.06 | $-0.12 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.5M | 392K | 566K | 7.3M |
| Operating Income | -55.5M | -59.3M | -61.9M | -42.4M |
| Net Income | -54.2M | -52.3M | -26.4M | -17.4M |
| Diluted EPS | $-0.77 | $-0.73 | $-0.37 | $-0.23 |